通过脑肠轴理论研究RTMS对帕金森病中便秘的治疗效果
Qianlan Bo1,2,3, Yanmin Li1,2,3, Xiayue Wang1,2,3
1Department of Neurology, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
Neurological research
|June 14, 2025
概括
通过调节脑肠轴因子,重复性跨体磁刺激 (rTMS) 显著改善了帕金森病 (PD) 患者的便秘和抑郁症. 这种非侵入性治疗为PD相关的胃肠道和情绪症状提供了有希望的治疗方法.
科学领域:
- 神经科学是一个神经科学.
- 胃肠病学 胃肠病学
- 精神病学是一个精神病学.
背景情况:
- 帕金森病 (PD) 经常涉及便秘,影响患者的生活质量.
- 大脑-肠轴理论表明,中枢神经系统功能障碍与PD中的胃肠道问题之间存在联系.
- 非侵入性神经调节技术,如rTMS正在探索PD症状管理.
研究的目的:
- 对帕金森病 (PD) 患者的便秘重复性跨磁刺激 (rTMS) 的治疗疗效进行调查.
- 探索RTMS作用的潜在机制,重点关注大脑-肠轴.
- 评估rTMS对便秘严重程度,肠道排便频率,抑郁症状和生活质量的影响.
主要方法:
- 一项随机对照试验,涉及58名患有便秘的PD患者.
- 治疗组接受了高频10 HzrTMS,准左脊侧前额皮质 (DLPFC);对照组接受了假刺激.
- 在14天的时间内,评估包括便秘严重程度 (CSS),肠道排便频率 (SBM,CSBM),抑郁症 (HAMD),脑肠,血清素,BDNF,炎症性细胞因子和生活质量 (PAC-QOL).
主要成果:
- 在rTMS组显示明显降低了便秘严重程度 (CSS) 和抑郁症得分 (HAMD).
- rTMS治疗导致自发排便 (SBM) 和完全自发排便 (CSBM) 频率增加.
- 在rTMS组中观察到血清素 (5-HT),脑衍生神经营养因子 (BDNF) 和脑肠的水平升高,以及炎症细胞因子 (IL-6,IL-8,IFN-γ) 的降低.
结论:
- 针对左侧DLPFC的重复性横磁刺激 (rTMS) 有效地改善了PD患者的便秘和抑郁症状.
- 治疗效益与大脑-肠轴的调节有关,包括神经递质和炎症通路.
- rTMS提供了一个有前途的,短期的辅助疗法,用于管理帕金森病的复杂症状.
相关概念视频
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
228
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
228
Parkinson's Disease: Treatment
239
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
239
Drugs for Treatment of Constipation-Predominant IBS
146
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
146
Drugs for Treatment of Diarrhea-Predominant IBS
153
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
153
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
281
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
281
Brain Imaging
219
Brain imaging technologies provide critical insights into both the structure and function of the human brain, enabling medical professionals and researchers to diagnose, study, and treat neurological disorders or psychiatric disorders more effectively.
These technologies include computerized axial tomography (CAT or CT scans), positron-emission tomography (PET scans), magnetic resonance imaging (MRI), functional magnetic resonance imaging (fMRI), and Transcranial Magnetic...
These technologies include computerized axial tomography (CAT or CT scans), positron-emission tomography (PET scans), magnetic resonance imaging (MRI), functional magnetic resonance imaging (fMRI), and Transcranial Magnetic...
219


